Allergy Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Allergy Therapeutics is Manuel Llobet, benoemd in Jul2009, heeft een ambtstermijn van 15.33 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 484.51K, bestaande uit 67.5% salaris en 32.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.1% van de aandelen van het bedrijf, ter waarde $ 333.14K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.9 jaar en 2.5 jaar.

Belangrijke informatie

Manuel Llobet

Algemeen directeur

UK£484.5k

Totale compensatie

Percentage CEO-salaris	67.5%
Dienstverband CEO	15.3yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	8.9yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Manuel Llobet's beloning veranderd ten opzichte van Allergy Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	UK£485k	UK£327k	-UK£40m
Mar 31 2024	n/a	n/a	-UK£45m
Dec 31 2023	n/a	n/a	-UK£50m
Sep 30 2023	n/a	n/a	-UK£47m
Jun 30 2023	UK£412k	UK£342k	-UK£43m
Mar 31 2023	n/a	n/a	-UK£36m
Dec 31 2022	n/a	n/a	-UK£29m
Sep 30 2022	n/a	n/a	-UK£21m
Jun 30 2022	UK£665k	UK£332k	-UK£14m
Mar 31 2022	n/a	n/a	-UK£10m
Dec 31 2021	n/a	n/a	-UK£5m
Sep 30 2021	n/a	n/a	-UK£1m
Jun 30 2021	UK£662k	UK£324k	UK£3m
Mar 31 2021	n/a	n/a	UK£5m
Dec 31 2020	n/a	n/a	UK£7m
Sep 30 2020	n/a	n/a	UK£7m
Jun 30 2020	UK£614k	UK£303k	UK£7m
Mar 31 2020	n/a	n/a	UK£8m
Dec 31 2019	n/a	n/a	UK£8m
Sep 30 2019	n/a	n/a	UK£6m
Jun 30 2019	UK£557k	UK£295k	UK£3m
Mar 31 2019	n/a	n/a	UK£117k
Dec 31 2018	n/a	n/a	-UK£3m
Sep 30 2018	n/a	n/a	-UK£5m
Jun 30 2018	UK£556k	UK£286k	-UK£8m

Compensatie versus markt: De totale vergoeding ($USD 608.93K ) Manuel } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.22M ).

Compensatie versus inkomsten: De vergoeding van Manuel is gestegen terwijl het bedrijf verliesgevend is.

CEO

Manuel Llobet (59 yo)

15.3yrs

Tenure

UK£484,506

Compensatie

Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limite...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Manuel Llobet	CEO & Executive Director	15.3yrs	UK£484.51k	0.10% $ 333.1k
Shaun Furlong	CFO & Executive Director	1.3yrs	UK£207.93k	0.000030% $ 95.4
Beverly Lees	Group Operations Director	8.9yrs	geen gegevens	geen gegevens
Murray Skinner	Chief Scientific Officer	8.9yrs	geen gegevens	geen gegevens
Santiago Puig	Business Development Director	15.1yrs	geen gegevens	geen gegevens
Sue Baker	Head of Human Resources	no data	geen gegevens	geen gegevens
Simon Piggott	Head of Clinical Science	7.2yrs	geen gegevens	geen gegevens
Alan Bullimore	Head of Communication & Market Development	no data	geen gegevens	geen gegevens
Russell Picket	Group Financial Controller	no data	geen gegevens	geen gegevens
Karley Charlotte Cheesman	Company Secretary	1.8yrs	geen gegevens	geen gegevens
Matthew Heath	Principal Scientist	no data	geen gegevens	geen gegevens

8.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van AGYT.F is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Manuel Llobet	CEO & Executive Director	15.3yrs	UK£484.51k	0.10% $ 333.1k
Shaun Furlong	CFO & Executive Director	less than a year	UK£207.93k	0.000030% $ 95.4
Babatunde Otulana	Senior Independent Director	7.4yrs	UK£44.50k	0.0010% $ 3.3k
Peter Jensen	Independent Chairman	14.1yrs	UK£94.00k	0.044% $ 139.9k
Johannes Ring	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Hendrik Kees Nolte	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anthony Frew	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lawrence Du Buske	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anthony Parker	Non-Executive Director	1.9yrs	geen gegevens	0.040% $ 128.2k
Cheryl Macdiarmid	Independent Non-Executive Director	3.1yrs	UK£41.13k	geen gegevens
Zheqing Shen	Non-Executive Director	1.9yrs	geen gegevens	0.0019% $ 6.0k
David William Ball	Independent Non-Executive Director	less than a year	UK£1.85k	geen gegevens

2.5yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AGYT.F wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Allergy Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Allergy Therapeutics plc, Annual General Meeting, Dec 16, 2024

Allergy Therapeutics plc Appoints David Ball as Non- Executive Director and Chair of the Board's Audit and Risk Committee

Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director

Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors

Allergy Therapeutics plc, Annual General Meeting, Mar 08, 2024

Allergy Therapeutics plc Announces Executive Changes

Recent updates

Allergy Therapeutics plc Submits Marketing Authorisation Application for Grass MATA MPL

Allergy Therapeutics plc, Annual General Meeting, Dec 16, 2024

Allergy Therapeutics plc Provides Revenue Guidance for the Second Half and Year Ended 30 June 2024

Allergy Therapeutics plc Appoints David Ball as Non- Executive Director and Chair of the Board's Audit and Risk Committee

Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL

Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director

Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024

Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors

Allergy Therapeutics plc, Annual General Meeting, Mar 08, 2024

Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL

Allergy Therapeutics plc Announces Interim Top Line Results from its Pivotal G306 Phase III Trial of Grass MATA MPL

Allergy Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.891025 million.

Allergy Therapeutics plc Announces the Completion of Dosing of Healthy Volunteers in the First Two Cohorts in the Phase I Protect Trial of Its Novel Virus-Like Particle (Vlp)-Based Peanut Allergy Vaccine Candidate

Allergy Therapeutics plc Announces Executive Changes

Allergy Therapeutics plc Provides Sales Guidance for the Second Half Year to 30 June 2023 and Full Year to 30 June 2024

Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended 31 December 2022

Allergy Therapeutics plc, Annual General Meeting, Feb 07, 2023

Allergy Therapeutics Announces Resignation of Scott Leinenweber as Non-Executive Director

Allergy Therapeutics Announces Key Updates on Grass MATA MPL and VLP Peanut Clinical Programmes

Allergy Therapeutics plc Announces Board Appointments

Allergy Therapeutics plc Appoints Martin Hopcroft as Interim CFO

Allergy Therapeutics plc Resumes UK Manufacturing Production

Allergy Therapeutics plc announced that it has received £17 million in funding from Southern Fox Investments Limited

Allergy Therapeutics plc announced that it expects to receive £10 million in funding from Southern Fox Investments Ltd. and other investor

Allergy Therapeutics plc, Annual General Meeting, Oct 17, 2022

Allergy Therapeutics plc Provides Revenue Guidance for the Year Ended 30 June 2022

Allergy Therapeutics plc Announces Resignation of Nick Wykeman to Its Board Director, Effective from November 30, 2022

Allergy Therapeutics Shares Data at WAO-BSACI

Allergy Therapeutics plc Announces the Presentation of Positive New Data from Its Two Lead Immunotherapy Programmes At the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting Held in Phoenix, Arizona

FDA Clears Allergy Therapeutics Investigational New Drug Application for Its Novel Virus-Like Particle (VLP )-Based Peanut Allergy Vaccine Candidate

Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended December 31, 2021

Allergy Therapeutics plc Announces the Secondary Endpoint Results from an Ex-Vivo Biomarker Study Vlp001

Allergy Therapeutics plc Provides Earnings Guidance for the Year 2021

Allergy Therapeutics plc Provides Earnings Guidance for the Full Year O 2021

Allergy Therapeutics plc Announces Steve Smith Step Down as Non-Executive Director

Allergy Therapeutics Announces an Ex-Vivo Biomarker Study of Blood Samples from Peanut Allergy Patients Has Begun At Imperial College London

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd